** Shares of drug developer Kymera Therapeutics KYMR.O rise 39.16% to $41.25 premarket
** Company says its experimental oral drug showed robust STAT6 degradation in blood and skin in early-stage trial
** The drug, KT-621, targets STAT6 — a signaling protein that plays a key role in immune response
** Company says results exceeded 90% STAT6 degradation target even at single doses as low as 6.25 mg
** KT-621 impact on biomarkers of Th2 immune response were in line or superior to Sanofi SASY.PA and Regeneron's REGN.O Dupixent - KYMR
** The study finds that KT-621 was as safe as the placebo, with no severe adverse events
** Up to last close, Kymera stock down ~26% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。